CA3127375A1 - Plasminogen for treating and preventing microthrombosis - Google Patents
Plasminogen for treating and preventing microthrombosis Download PDFInfo
- Publication number
- CA3127375A1 CA3127375A1 CA3127375A CA3127375A CA3127375A1 CA 3127375 A1 CA3127375 A1 CA 3127375A1 CA 3127375 A CA3127375 A CA 3127375A CA 3127375 A CA3127375 A CA 3127375A CA 3127375 A1 CA3127375 A1 CA 3127375A1
- Authority
- CA
- Canada
- Prior art keywords
- plasminogen
- patient
- plg
- administered
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19153572.3 | 2019-01-24 | ||
| EP19153572 | 2019-01-24 | ||
| PCT/EP2020/051733 WO2020152322A1 (en) | 2019-01-24 | 2020-01-24 | Plasminogen for treating and preventing microthrombosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3127375A1 true CA3127375A1 (en) | 2020-07-30 |
Family
ID=65234430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3127375A Pending CA3127375A1 (en) | 2019-01-24 | 2020-01-24 | Plasminogen for treating and preventing microthrombosis |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220072110A1 (https=) |
| EP (1) | EP3914288A1 (https=) |
| JP (1) | JP2022518496A (https=) |
| KR (1) | KR20210119428A (https=) |
| CN (1) | CN113597313A (https=) |
| AU (1) | AU2020212404B2 (https=) |
| BR (1) | BR112021014068A2 (https=) |
| CA (1) | CA3127375A1 (https=) |
| WO (1) | WO2020152322A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022258590A1 (en) | 2021-06-08 | 2022-12-15 | Previpharma Consulting Gmbh | Process for isolating plasminogen from a blood plasma fraction |
| WO2025132796A1 (en) | 2023-12-21 | 2025-06-26 | Previpharma Consulting Gmbh | Process for isolating glu-plasminogen from a solution |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2254316B1 (https=) * | 1973-12-18 | 1977-04-22 | Choay Sa | |
| US5520912A (en) | 1993-07-02 | 1996-05-28 | Immuno Aktiengesellschaft | Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen |
| TWI801331B (zh) * | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
| ES2982294T3 (es) * | 2015-12-18 | 2024-10-15 | Talengen Int Ltd | Plasminógeno para su uso en el tratamiento o prevención de lesiones nerviosas por diabetes mellitus |
| ES2968254T3 (es) * | 2015-12-18 | 2024-05-08 | Talengen Int Ltd | Plasminógeno para su uso en la prevención o el tratamiento de la trombosis aguda y la trombosis crónica |
| DK3391902T5 (da) * | 2015-12-18 | 2024-09-23 | Talengen Int Ltd | Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati |
| KR102640024B1 (ko) * | 2017-03-09 | 2024-02-22 | 프리비파하르마, 컨설팅 게엠베하 | 혈액 분획으로부터의 Glu-플라스미노겐의 제조 및 용도 |
-
2020
- 2020-01-24 AU AU2020212404A patent/AU2020212404B2/en active Active
- 2020-01-24 KR KR1020217025524A patent/KR20210119428A/ko not_active Ceased
- 2020-01-24 JP JP2021542366A patent/JP2022518496A/ja active Pending
- 2020-01-24 CA CA3127375A patent/CA3127375A1/en active Pending
- 2020-01-24 US US17/422,962 patent/US20220072110A1/en active Pending
- 2020-01-24 BR BR112021014068-9A patent/BR112021014068A2/pt unknown
- 2020-01-24 EP EP20703164.2A patent/EP3914288A1/en active Pending
- 2020-01-24 CN CN202080021518.7A patent/CN113597313A/zh active Pending
- 2020-01-24 WO PCT/EP2020/051733 patent/WO2020152322A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020212404B2 (en) | 2025-11-27 |
| WO2020152322A1 (en) | 2020-07-30 |
| KR20210119428A (ko) | 2021-10-05 |
| JP2022518496A (ja) | 2022-03-15 |
| EP3914288A1 (en) | 2021-12-01 |
| US20220072110A1 (en) | 2022-03-10 |
| CN113597313A (zh) | 2021-11-02 |
| AU2020212404A1 (en) | 2021-08-26 |
| BR112021014068A2 (pt) | 2021-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gold et al. | Coronary thrombolysis with recombinant human tissue-type plasminogen activator. | |
| Jansen et al. | Use of tranexamic acid for an effective blood conservation strategy after total knee arthroplasty | |
| McKenna | Abnormal coagulation in the postoperative period contributing to excessive bleeding | |
| Larsson et al. | Valproic acid selectively increases vascular endothelial tissue‐type plasminogen activator production and reduces thrombus formation in the mouse | |
| CA2684075A1 (en) | Providing hemostasis in anticoagulated blood by using zeolites | |
| Graor et al. | Peripheral artery and bypass graft thrombolysis with recombinant human tissue-type plasminogen activator | |
| CN110612350A (zh) | 源自血液的谷氨酸-纤溶酶原的制备和使用 | |
| Weitz et al. | Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis. | |
| AU2020212404B2 (en) | Plasminogen for treating and preventing microthrombosis | |
| Schulman | Studies on the medical treatment of deep vein thrombosis | |
| US20220184189A1 (en) | Methods for safe and effective thrombolysis using sequential administration of tissue plasminogen activator and mutant pro-urokinase | |
| AU2014209886B2 (en) | Hemostatic compositions | |
| RU2714112C2 (ru) | Терапевтическая APAC-молекула, содержащая гепарин, конъюгированный с белком плазмы крови | |
| LeVeen et al. | Venous and arterial occlusive disease treated by enzymatic clot lysis | |
| RU2813699C2 (ru) | Плазминоген для лечения и профилактики микротромбоза | |
| Novacek et al. | Enhanced blood coagulation and enhanced fibrinolysis during hemodialysis with prostacyclin | |
| Cortese et al. | Idarucizumab: what should we know? | |
| Tai et al. | A case of warfarin skin necrosis despite enoxaparin anticoagulation in a patient with protein S deficiency | |
| AU2013366544B2 (en) | Sealant compositions | |
| Cole et al. | Ancrod versus heparin for anticoagulation during vascular surgical procedures | |
| Bhagirath et al. | Management of bleeding complications in the anticoagulated patient | |
| Chesterman et al. | Thrombolytic therapy with streptokinase | |
| CN114096259A (zh) | 用于缺血性中风的治疗和二级预防的ld肝素 | |
| Giles et al. | The thrombogenicity of prothrombin complex concentrates: III. The relationship of in vivo thrombogenicity to the nature of the starting plasma | |
| Hoefer et al. | Locally applied recombinant plasmin results in effective thrombolysis in a porcine model of arteriovenous graft thrombosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240116 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250107 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250107 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250107 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250623 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251023 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251218 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251218 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251218 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260114 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260114 |